Is MLYS or MREO more undervalued in 2026?

CirclFi compares Mineralys Therapeutics, Inc. (MLYS) and Mereo BioPharma Group plc (MREO) using 13 institutional-grade valuation models. MLYS has a Quality of Company score of 4.3/10 while MREO scores 5.0/10.

Which is a better buy — MLYS or MREO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MLYS and MREO valuations compare?

MLYS at $31.54 and MREO at $0.34 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MLYS vs MREO Valuation Comparison 2026 — Intrinsic Value Analysis

MLYS

Biotechnology

Mineralys Therapeutics, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$31.54

Last close

Models

10/13

Active

MREO

Biotechnology

Mereo BioPharma Group plc

Quality

5.0

out of 10

Value Trap

SAFE

Price

$0.34

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	MLYS Fair Value	MLYS Upside	MREO Fair Value	MREO Upside
Bayesian DCF	Intrinsic	$10.20	-67.6%	$0.17	-50.7%
Earnings Power Value	Intrinsic	$14.31	-48.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$6.22	-80.3%	$0.85	+146.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MLYS vs MREO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MLYS vs MREO — Which Stock Is More Undervalued?

MREO scores higher with a 5.0/10 quality rating vs MLYS's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Mineralys Therapeutics, Inc. (MLYS) and Mereo BioPharma Group plc (MREO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MLYS currently trades at $31.54 with a QOC of 4.3/10, while MREO trades at $0.34 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).